|Mr. Mark Ahrens-Townsend B.Sc. (Eng.) MBA||Chief Exec. Officer, Pres & Director||229.89k||N/A||N/A|
|Mr. L. Michael Coutts||Director of Bus. Devel.||N/A||N/A||N/A|
|Mr. Grant Humphrey||VP of Sales||N/A||N/A||N/A|
|Dr. Tony Romeo||Chief Scientific Advisor and Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. P. Marcus Enns B.Comm. (Hons.)||VP of Corp. Affairs||N/A||N/A||38|
Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms. It develops wound care solutions under the DispersinB and AloSera trademarks; medical device coatings under the Aledex trademark; and pet oral care solutions under the StrixNB and bluestem trademarks. The company also offers its products under the coactive+ and Kane trademarks. In addition, it offers KBI Antibacterial Disinfectant. The company was founded in 2001 and is based in Winnipeg, Canada.
Kane Biotech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.